CLS Therapeutic Lifestyle & Pharmacologic Interventions 2

Question 1

A patient on high-intensity statin therapy has LDL-C still above goal. Which add-on therapy has demonstrated cardiovascular event reduction in a dedicated outcomes trial?

Accepted Answer

Ezetimibe

Answer

The IMPROVE-IT trial demonstrated that ezetimibe added to simvastatin significantly reduced major cardiovascular events compared to simvastatin alone.

Question 2

Which dietary fat substitution has the greatest evidence for reducing LDL-C when replacing saturated fat?

Accepted Answer

Polyunsaturated fatty acids

Answer

Replacing saturated fat with polyunsaturated fatty acids (PUFAs) produces the greatest LDL-C reduction and improves the LDL/HDL ratio.

Question 3

A patient with severe hypertriglyceridemia (TG >1000 mg/dL) is at highest immediate risk for which complication?

Accepted Answer

Acute pancreatitis

Answer

Severely elevated triglycerides (>1000 mg/dL) pose the greatest immediate risk of acute pancreatitis, which can be life-threatening.

Question 4

Inclisiran differs mechanistically from PCSK9 monoclonal antibodies in that it:

Accepted Answer

Inhibits PCSK9 synthesis via RNA interference

Answer

Inclisiran is a small interfering RNA (siRNA) that reduces hepatic PCSK9 synthesis, leading to sustained LDL-C lowering with twice-yearly dosing.

Question 5

In the TLC (Therapeutic Lifestyle Changes) diet, what is the recommended daily dietary cholesterol intake?

Accepted Answer

< 200 mg/day

Answer

The NCEP TLC diet recommends limiting dietary cholesterol to less than 200 mg/day to reduce LDL-C.

(CLS) Clinical Lipid Specialist Certification Practice Test

(CLS) Clinical Lipid Specialist Certification Practice Test

CLS Therapeutic Lifestyle & Pharmacologic Interventions 2